Ribociclib & Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Conditions: Metastatic Breast Cancer; Recurrent Ovarian Carcinoma Interventions: Drug: Ribociclib; Drug: Belinostat Sponsors: University of Utah; Novartis; Acrotech Biopharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Ovarian Cancer | Ovaries | Research